Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | RAF1 | P04049 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | MRGPRX1 | Q96LB2 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439239 | 0.84 | NOTUM (0.51) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL1604973 | 0.84 | NOTUM (0.51) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL10325524 | 0.81 | NOTUM (0.49) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL438064 | 0.81 | NOTUM (0.49) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL10343795 | 0.81 | LIMK1 (0.44) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL6911943 | 0.79 | LIMK1 (0.66) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL6120297 | 0.78 | NOTUM (0.52) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL6642198 | 0.76 | LIMK1 (0.61) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL13644138 | 0.76 | LIMK1 (0.61) | LIMK1L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL2404424 | 0.75 | HSD17B10 (0.45) | LMNAALDH1A1HPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017935-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-01-16 | — | — | US | disclosed |
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| EP-4255893-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | The Johns Hopkins University (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11679111-B2 | Fatty acid synthase inhibitors | DUKE UNIVERSITY (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023064587-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064587-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022119823-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20210338676-A1 | FATTY ACID SYNTHASE INHIBITORS | DUKE UNIVERSITY (US) | 2021-11-04 | — | — | US | disclosed |
| US-10966981-B2 | Fatty acid synthase inhibitors | DUKE UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| EP-2955185-B1 | POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF | SHANGHAI FOSUN PHARMACEUTICAL DEV CO LTD (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1724268-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
| CN-1777612-A | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | PREDIX PHARMACEUTICALS HOLDING (US) | 2006-05-24 | — | — | CN | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | PGXHEALTH, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR5A, HTR3A, HTR1A | LIMK1 2778/4885L3MBTL1 4685/4885LMNA 2240/4885 |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | LIMK1 4297/4885L3MBTL1 4774/4885LMNA 3223/4885 |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, API5 | LIMK1 4251/4885L3MBTL1 1350/4885LMNA 822/4885 |
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | MRGPRX1, MRGPRX4, MRGPRX2 | LIMK1 2881/4885L3MBTL1 4171/4885LMNA 4368/4885 |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR2B, HTR3B, HTR1B | LIMK1 3892/4885L3MBTL1 4693/4885LMNA 3979/4885 |
| US-20250017935-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | LIMK1 3270/4885L3MBTL1 2433/4885LMNA 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.